Author + information
- Purushothaman K-Raman,
- Meerarani Purushothaman,
- Prakash Krishnan,
- Usman Baber,
- Urooz Zafar,
- Annapoorna Kini,
- Samin Sharma,
- Juan Badimon,
- Valentin Fuster and
- Pedro Moreno
Background: Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) plays a major role in the regulation of hepatic low density lipoprotein (LDL) and cholesterol level. However, the expression of PCSK9 in extra hepatic tissues, especially in atherosclerotic plaques has not been characterized.
Methods: We have randomly selected 40 human aortic atherosclerotic plaques derived at autopsy. Plaques were stained by Hematoxylin and Eosin for morphological characterization according to AHA classification. Lipid rich plaques (23) were further scored based on lipid core expansion in the intima, as lipid poor (< 50%) and lipid rich (> 50%) and similarly fibrous plaques (17) were graded as fibrosis poor (< 50%) and fibrosis rich (> 50%). PCSK9 was quantified by immunohistochemistry and scored by cellular expression in all the plaques.
Results: Lipid rich plaques showed increased PCSK9 protein expression compared to lipid poor (2.51 ± 0.13 vs. 1.37 ± 0.21; p=0.0001). Whereas, fibrous rich plaques showed decreased PCSK9 protein expression compared to fibrous poor (1.77 ± 0.20 Vs. 2.38 ± 0.18; p= 0.0001). (Figure) Linear regression analysis identified a relation between PCSK9 expression and lipid rich plaques (r=0.613; p=.0.0001).
Conclusions: Our results suggest PCSK9 protein expression is increased in lipid rich human atherosclerotic plaques compared to fibrous plaques. The pathological consequences of these finding are evolving and remains to be elucidated.
Poster Hall, Hall C
Saturday, March 18, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Cutting Edge Vascular Medicine
Abstract Category: 38. Vascular Medicine: Basic
Presentation Number: 1205-355
- 2017 American College of Cardiology Foundation